地舒单抗在中国上市了吗？

In June 2010, the US FDA approved (trade name: Prolia, also known as denosumab in China) for the treatment of osteoporosis in postmenopausal women. It was later approved for the treatment of male osteoporosis, bone loss caused by androgen deprivation therapy for prostate cancer, and bone loss caused by aromatase inhibitor therapy for breast cancer.

Desosumab (denosumab) is a bone resorption inhibitor with a unique mechanism of action. It specifically targets receptor activator of nuclear factor kappa B (RANK) ligand, inhibits the activation and development of osteoclasts, reduces bone resorption, and increases bone density.

Is denosumab available in China?

On May 27, 2019, Amgen China announced the launch of denosumab (denosumab) in my country for the treatment of giant cell tumors of bone that are unresectable or whose surgical resection may lead to severe dysfunction, including adults and adolescent patients with mature bone development (defined as at least 1 mature long bone and body weight >45 kg). This approval makes denosumab the first and currently the only drug for the treatment of giant cell tumor of bone, bringing patients an innovative treatment option to control disease progression and improve quality of life.

Desosumab (denosumab) has not been on the market for a long time in my country, and many patients are not particularly familiar with it. In terms of its therapeutic effect in preventing osteoporosis in postmenopausal women, denosumab significantly increased vertebral BMD compared with placebo (a 6.5% increase in the treatment group versus a 0.6% decrease in the placebo group). In addition, the BMD values ​​of all tested parts such as the hip bone and distal radius in the treatment group increased significantly.

The launch of (denosumab) in China provides a new treatment option for domestic patients and is a good choice for patients. If you have other questions, you can consult the medical companion passenger service for more relevant information.